The use of opioid in treating a patient with kratom use disorder: A case report
More details
Hide details
Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, MALAYSIA
Hospital Universiti Sains Malaysia, Jalan Raja Perempuan Zainab II, Kubang Kerian, Kelantan, MALAYSIA
Klinik Kesihatan Kuala Besut, Kuala Besut, Terengganu, MALAYSIA
Klinik Kesihatan Masjid Tanah, Masjid Tanah, Melaka, MALAYSIA
Online publication date: 2023-03-11
Publication date: 2023-05-01
Electron J Gen Med 2023;20(3):em482
Kratom is a botanical plant product that is used around the world, particularly in Southeast Asia. It is believed that it has potential benefits as a painkiller and for relieving fatigue. Specifically, kratom can produce an opioid effect, which makes it addictive. We report a 26-year-old man who presented to the clinic for treatment of kratom use disorder. He was willing to be treated because he could no longer withstand the withdrawal effect and the financial cost of his addiction. Our team successfully initiated treatment using buprenorphine-naloxone (suboxone) in pill form to treat his kratom use disorder. The patient also received non-pharmacological treatment such as psychoeducation, psychotherapy, and motivational interviews. He was successfully treated with suboxone and within a week he was kratom free and happy.
Eastlack SC, Cornett EM, Kaye AD. Kratom–Pharmacology, clinical implications, and outlook: A comprehensive review. Pain Ther. 2020;9(1):55-69. PMid:31994019 PMCid:PMC7203303.
Singh D, Müller CP, Vicknasingam BK. Kratom (mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132-7. PMid:24698080.
Chang-Chien GC, Odonkor CA, Amorapanth P. Is kratom the new “legal high” on the block?: The case of an emerging opioid receptor agonist with substance abuse potential. Pain Physician. 2017;20(1):E195-8.
Broyan VR, Brar JK, Student TA, Allgaier JT. Long-term buprenorphine treatment for kratom use disorder: A case series. Subst Abus. 2022;43(1):763-6. PMid:35112990.
Gittins R, Cole S. Buprenorphine for the management of kratom dependency during COVID-19: A case report. Drug Sci Policy Law. 2021;7:205032452110211.
Schmuhl KK, Gardner SM, Cottrill CB, Bonny AE. Home induction and outpatient treatment of kratom use disorder with buprenorphine-naloxone: A case report in a young adult. Subst Abus. 2020;41(3):311-4. PMid:31644379.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. American Psychiatric Association; 2013.
Stanciu CN, Gnanasegaram SA, Ahmed S, Penders T. Kratom withdrawal: A systematic review with case series. J Psychoactive Drugs. 2019;51(1):12-8. PMid:30614408.
Lei J, Butz A, Valentino N. Management of kratom dependence with buprenorphine/naloxone in a veteran population. Subst Abus. 2021;42(4):497-502. PMid:33617752.
Sablaban IM, Gautam M. The diagnosis of severe obsessions in the setting of kratom withdrawal and treatment with lorazepam: Case report. J Addict Dis. 2020;39(1):138-9. PMid:32924857.
Bowe A, Kerr PL. A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: Effects of buprenorphine in clinical management. J Psychoactive Drugs. 2020;52(5):447-52. PMid:32546067.
Journals System - logo
Scroll to top